Collaborative Fund Advisors LLC Purchases New Holdings in Gilead Sciences, Inc. $GILD

Collaborative Fund Advisors LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,863 shares of the biopharmaceutical company’s stock, valued at approximately $576,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bfsg LLC boosted its position in shares of Gilead Sciences by 7.7% during the 3rd quarter. Bfsg LLC now owns 1,003 shares of the biopharmaceutical company’s stock valued at $149,000 after acquiring an additional 72 shares during the last quarter. Chicago Partners Investment Group LLC lifted its position in shares of Gilead Sciences by 41.8% during the third quarter. Chicago Partners Investment Group LLC now owns 14,288 shares of the biopharmaceutical company’s stock worth $2,229,000 after purchasing an additional 4,209 shares during the last quarter. Covestor Ltd lifted its position in shares of Gilead Sciences by 21.5% during the third quarter. Covestor Ltd now owns 876 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 155 shares during the last quarter. Caldwell Trust Co boosted its stake in shares of Gilead Sciences by 39.3% during the third quarter. Caldwell Trust Co now owns 1,705 shares of the biopharmaceutical company’s stock valued at $254,000 after purchasing an additional 481 shares during the period. Finally, 3Chopt Investment Partners LLC boosted its stake in shares of Gilead Sciences by 0.8% during the third quarter. 3Chopt Investment Partners LLC now owns 22,751 shares of the biopharmaceutical company’s stock valued at $3,391,000 after purchasing an additional 180 shares during the period. Institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares of the company’s stock, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 126,881 shares of company stock valued at $19,252,455 over the last quarter. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on GILD. TD Cowen raised their price objective on Gilead Sciences from $160.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Wells Fargo & Company upped their target price on Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Jefferies Financial Group set a $196.00 price target on Gilead Sciences in a research report on Wednesday. Needham & Company LLC set a $175.00 price target on Gilead Sciences in a research note on Friday, October 30th. Finally, Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Twenty-three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $170.15.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Gilead Sciences Price Performance

Shares of GILD opened at $174.48 on Thursday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 0.95. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $175.65. The firm has a market capitalization of $216.41 billion, a PE ratio of -55.22 and a beta of 0.35. The company’s fifty day moving average price is $152.29 and its 200-day moving average price is $140.52.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the company earned $2.47 EPS. On average, equities research analysts predict that Gilead Sciences, Inc. will post -1.07 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.